53 related articles for article (PubMed ID: 16481384)
1. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.
Dooms CA; Lievens YN; Vansteenkiste JF
Eur Respir J; 2006 May; 27(5):895-901. PubMed ID: 16481384
[TBL] [Abstract][Full Text] [Related]
2. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
3. Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis.
Lam M; Olivier T; Haslam A; Tuia J; Prasad V
Eur J Cancer; 2024 May; 202():114019. PubMed ID: 38522156
[No Abstract] [Full Text] [Related]
4. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
6. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.
Walleser S; Ray J; Bischoff H; Vergnenègre A; Rosery H; Chouaid C; Heigener D; de Castro Carpeño J; Tiseo M; Walzer S
Clinicoecon Outcomes Res; 2012; 4():269-75. PubMed ID: 23028234
[TBL] [Abstract][Full Text] [Related]
7. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.
Joerger M; Matter-Walstra K; Früh M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Ann Oncol; 2011 Mar; 22(3):567-574. PubMed ID: 20843984
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
Carlson JJ; Canestaro W; Ravelo A; Wong W
J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
13. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
Nelson RE; Stenehjem D; Akerley W
Lung Cancer; 2013 Dec; 82(3):461-8. PubMed ID: 24074609
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
15. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of Palliative Care for Patients with Cancer Disease: A Systematic Review.
Soltani Arabshahi SK; Nikjoo S; Rezapour A; Rashki Kemmak A; Jahangiri R; Farabi H; Husseini Barghazan S
Med J Islam Repub Iran; 2022; 36():141. PubMed ID: 36569396
[No Abstract] [Full Text] [Related]
18. The experience of providing hospice care concurrent with cancer treatment in the VA.
Haverhals LM; Manheim CE; Mor V; Ersek M; Kinosian B; Lorenz KA; Faricy-Anderson KE; Gidwani-Marszowski RA; Levy C
Support Care Cancer; 2019 Apr; 27(4):1263-1270. PubMed ID: 30467792
[TBL] [Abstract][Full Text] [Related]
19. The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.
Wichmann AB; Adang EM; Stalmeier PF; Kristanti S; Van den Block L; Vernooij-Dassen MJ; Engels Y;
Palliat Med; 2017 Apr; 31(4):306-322. PubMed ID: 28190374
[TBL] [Abstract][Full Text] [Related]
20. Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.
Chandrasekar D; Tribett E; Ramchandran K
Curr Treat Options Oncol; 2016 May; 17(5):23. PubMed ID: 27032645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
